Contact | Site Map

Cytogenix Home » Company » Press Release : May 2006
Press Release : May 2006
« Back

Senior Biotech Scientist Joins CytoGenix to Head synDNA Manufacturing Group

Houston, TX (May 18, 2006) CytoGenix, Inc. (CYGX: OTC: BB) announces that Michael Y. Ma, Ph.D. has agreed to join the company as Director of DNA Production. Formerly a Project Manager and Head of Organic Chemistry and Oligo Synthesis at Promega Corporation, Madison, Wisconsin, Dr. Ma has 15 years of biotech industry experience in various scientific and operations management positions.

Dr. Ma will direct the scale-up and expansion of the company's synthetic DNA manufacturing process, including developing and testing standard methods for production and quality control. His duties include directing the construction of a new manufacturing facility.

Frank Vazquez, CytoGenix, Executive Vice President and COO, states, "Michael is an outstanding scientist and manager with excellent industry experience; his organic and nucleic acid chemistry training as well as his hands-on custom reagent manufacturing experience, make him the ideal person for this position."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA _expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.

Contact: Frank Vazquez (713) 789-0070.